Allergan/Richter’s Antipsychotic Vraylar Offers New Mechanism Of Action
This article was originally published in The Pink Sheet Daily
Executive Summary
Schizophrenia and bipolar disorder treatment will launch in first quarter of 2016.
You may also be interested in...
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
The latest drug development news and highlights from our FDA Performance Tracker.
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
The latest drug development news and highlights from our FDA Performance Tracker.
Allergan Confident Data Support Bipolar Depression Addition To Vraylar's Label
After recording its third positive pivotal trial in bipolar depression, Allergan will now file an sNDA for Vraylar in the second half of 2018.